Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 68Lung Neoplasms 18Neoplasms 7Neoplasm Metastasis 7Melanoma 5Carcinoma 5Mesothelioma, Malignant 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Non-Squamous Non-small Cell Lung Cancer 2Non-Small Cell Lung Cancer Metastatic 2Non Small Cell Lung Carcinoma NSCLC 2Mesothelioma 2Endometrial Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Resectable Stage IIA to IIIB Non-small Cell Lung Cancer 1Resectable Non-small Cell Lung Cancer 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2cemiplimab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Resectable Non-small Cell Lung Cancer × Pemetrexed × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡